« Back
Home /
CMX-2043

CMX-2043

Item no.	HY-119152-10mg
Manufacturer	MedChem Express
CASRN	910627-26-8
Amount	10 mg
Quantity options	10 mg 1 ea 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.42
Citations	[1]Alan S Lader, et al. CMX-2043 Mechanisms of Action In Vitro. J Cardiovasc Pharmacol. 2016 Sept;68:241-247. \|[2]Baguisi A, et al. CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury. J Cardiovasc Pharmacol Ther. 2016 Nov;21(6):563-569.
Smiles	C[C@H](NC([C@@H](NC(CCCC[C@H]1SSCC1)=O)CCC(O)=O)=O)C(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Akt; Insulin Receptor; Tyrosinase
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight	406.52
Product Description	CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model[1][2].
Manufacturer - Research Area	Others
Solubility	DMSO: 20.83 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-119152-10mg-safety-datasheet.pdf